TY - JOUR
T1 - The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography
AU - Efrati, Shai
AU - Dishy, Victor
AU - Averbukh, Michael
AU - Blatt, Alex
AU - Krakover, Ricardo
AU - Weisgarten, Joshua
AU - Morrow, Jason D.
AU - Stein, Michael C.
AU - Golik, Ahuva
N1 - Funding Information:
This study was supported by USPHS grants HL 56251, GM 5MO1-RR0095, HL 65082, HL 04012, GM 15431, DK 48831, CA 77839, and DK 26657. Dr. Morrow is the recipient of a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.
PY - 2003/12
Y1 - 2003/12
N2 - Background. Renal failure induced by radiographic contrast agents is a known complication of coronary angiography, especially among patients with chronic renal failure. Recently, treatment with N-acetylcysteine (NAC) has been shown to have a protective effect but the mechanisms are unknown. We examined the hypothesis that NAC protected against contrast-induced renal impairment through effects on nitric oxide metabolism and oxidative stress. Methods. Patients with a serum creatinine concentration above 106 μmol/L undergoing coronary angiography were randomly assigned to receive either NAC 1 g (N = 24) or placebo (N = 29) twice daily 24 hours before and after angiography with 0.45 % saline hydration in a double-blind study. Creatinine clearance was calculated and urinary nitric oxide and F2-isoprostane excretion were measured at baseline, 24 and 96 hours after angiography. Results. Treatment with NAC significantly improved the effect of contrast media on creatinine clearance, and maximal beneficial effect was observed 24 hours after angiography. Creatinine clearance (mL/min) was 59.5 ± 4.4, 64.7 ± 5.8, and 58.7 + 3.9 at baseline, 24, and 96 hours after angiography in the NAC group, respectively, and 65.2 ± 3.2, 51.5 ± 3.7, and 53.6 ± 3.9 in the placebo group, respectively (P < 0.0001). NAC treatment prevented the reduction in urinary nitric oxide after angiography. The urinary nitric oxide/creatinine ratio (μmol/mg) was 0.0058 ± 0.0004, 0.0057 ± 0.0004, and 0.0052 ± 0.0004 at baseline, 24, and 96 hours after angiography in NAC group, respectively, and 0.0057 ± 0.0007, 0.0031 ± 0.0005, and 0.0039 ± 0.0005 in the placebo group, respectively (P = 0.013). NAC had no significant effect on urinary F2-isoprostanes. Conclusion. NAC treatment has renoprotective effect in patients with mild chronic renal failure undergoing coronary angiography that may be mediated in part by an increase in nitric oxide production.
AB - Background. Renal failure induced by radiographic contrast agents is a known complication of coronary angiography, especially among patients with chronic renal failure. Recently, treatment with N-acetylcysteine (NAC) has been shown to have a protective effect but the mechanisms are unknown. We examined the hypothesis that NAC protected against contrast-induced renal impairment through effects on nitric oxide metabolism and oxidative stress. Methods. Patients with a serum creatinine concentration above 106 μmol/L undergoing coronary angiography were randomly assigned to receive either NAC 1 g (N = 24) or placebo (N = 29) twice daily 24 hours before and after angiography with 0.45 % saline hydration in a double-blind study. Creatinine clearance was calculated and urinary nitric oxide and F2-isoprostane excretion were measured at baseline, 24 and 96 hours after angiography. Results. Treatment with NAC significantly improved the effect of contrast media on creatinine clearance, and maximal beneficial effect was observed 24 hours after angiography. Creatinine clearance (mL/min) was 59.5 ± 4.4, 64.7 ± 5.8, and 58.7 + 3.9 at baseline, 24, and 96 hours after angiography in the NAC group, respectively, and 65.2 ± 3.2, 51.5 ± 3.7, and 53.6 ± 3.9 in the placebo group, respectively (P < 0.0001). NAC treatment prevented the reduction in urinary nitric oxide after angiography. The urinary nitric oxide/creatinine ratio (μmol/mg) was 0.0058 ± 0.0004, 0.0057 ± 0.0004, and 0.0052 ± 0.0004 at baseline, 24, and 96 hours after angiography in NAC group, respectively, and 0.0057 ± 0.0007, 0.0031 ± 0.0005, and 0.0039 ± 0.0005 in the placebo group, respectively (P = 0.013). NAC had no significant effect on urinary F2-isoprostanes. Conclusion. NAC treatment has renoprotective effect in patients with mild chronic renal failure undergoing coronary angiography that may be mediated in part by an increase in nitric oxide production.
KW - Contrast media
KW - N-acetylcysteine
KW - Nitric oxide
KW - Oxidative stress
KW - Renal failure
UR - http://www.scopus.com/inward/record.url?scp=0344945450&partnerID=8YFLogxK
U2 - 10.1046/j.1523-1755.2003.00322.x
DO - 10.1046/j.1523-1755.2003.00322.x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 14633141
AN - SCOPUS:0344945450
SN - 0085-2538
VL - 64
SP - 2182
EP - 2187
JO - Kidney International
JF - Kidney International
IS - 6
ER -